NT5E and neoplasm: They demonstrated that inhibition of CD73 activity, both individually and, especially, in combination SCH58261, enhanced the potency of DC vaccines to induce more effective antitumor immune responses, inhibit retarded tumor growth, and prolong the survival of tumor-bearing mice [138].